Table 5.
Top 10 most global cited documents in the field of breast cancer immunotherapy resistance from 2003 to 2024.
| Rank | Documents | Year | First author | Journal | DOI | Total citations |
|---|---|---|---|---|---|---|
| 1 | Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response | 2018 | Jiang P | Nature Medicine | 10.1038/s41591-018-0136-1 | 2409 |
| 2 | Top 10 Challenges in Cancer Immunotherapy | 2020 | Hegde PS | Immunity | 10.1016/j.immuni.2019.12.011 | 1018 |
| 3 | Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment | 2009 | Lee YJ | Blood | 10.1182/blood-2009-02-206870 | 1003 |
| 4 | CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy | 2018 | Tokunaga R | Cancer Treatment Reviews | 10.1016/j.ctrv.2017.11.007 | 743 |
| 5 | Overview of resistance to systemic therapy in patients with breast cancer | 2007 | Gonzalez-Angulo AM | Advances in Experimental Medicine and Biology | 10.1007/978-0-387-74039-3_1 | 703 |
| 6 | Sphingolipid metabolism in cancer signalling and therapy | 2018 | Ogretmen B | Nature Reviews Cancer | 10.1038/nrc.2017.96 | 671 |
| 7 | Tumorigenic and Immunosuppressive Effects of Endoplasmic Reticulum Stress in Cancer | 2017 | Cubillos-Ruiz JR | Cell | 10.1016/j.cell.2016.12.004 | 547 |
| 8 | Microenvironmental regulation of therapeutic response in cancer | 2015 | Klemm F | Trends in Cell Biology | 10.1016/j.tcb.2014.11.006 | 509 |
| 9 | Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation | 2017 | Allen E | Science Translational Medicine | 10.1126/scitranslmed.aak9679 | 505 |
| 10 | Breast Cancer Immunotherapy: Facts and Hopes | 2018 | Emens LA | Clinical Cancer Research | 10.1158/1078-0432.CCR-16-3001 | 495 |